表紙：BRAFキナーゼ阻害剤の世界市場：薬剤別、適応症別、流通チャネル別、地域別-規模、シェア、展望、機会分析-2022～2028年

市場調査レポート

商品コード

1085723

BRAFキナーゼ阻害剤の世界市場：薬剤別、適応症別、流通チャネル別、地域別-規模、シェア、展望、機会分析-2022～2028年

BRAF Kinase Inhibitors Market, by Drug, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

出版日: 2022年05月21日 | 発行: Coherent Market Insights

| ページ情報: 英文 158 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF (Single User License)

USD 4,500 701,325円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は一度のみ可能です。印刷したもののご利用はPDFのライセンス保持者に限定されます。

PDF (Multi User License)

USD 7,000 1,090,950円

レポートPDFを7名までにてご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペーストは可能です。PDFの印刷は7回まで可能です。印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise User License)

USD 10,000 1,558,500円

レポートPDFを同一企業およびその子会社のすべての方に使用頂けるライセンスです。PDF内のテキスト等のコピーは可能です。PDFの印刷回数に制限はありません。印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=155.85円

全表示
概要
目次

概要

サンプル依頼リストに入れる

世界のBRAFキナーゼ阻害剤市場の主要企業は、特許の取得に注力しており、新興国のメーカーにとってより多くの機会を創出することが期待されます。しかし、市場における課題の一つは、患者の負担です。高コストであるため、患者は実際の治療体制からがん治療の代替手段にシフトしています。

当レポートでは、世界のBRAFキナーゼ阻害剤市場について調査分析し、市場の促進要因、抑制要因、市場機会、薬剤・適応症・流通チャネル・地域別市場分析、企業プロファイルに関する情報を提供しています。

BRAF is a kinase enzyme that helps control cell growth and signalling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins may help keep cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. Two compounds (vemurafenib and dabrafenib) have achieved approval by the Food and Drug Administration (FDA) for the treatment of metastatic and unresectable BRAF-mutated melanomas.

Market Dynamics

Key players in the BRAF kinase inhibitors market are focusing on obtaining patents, which is expected to create more opportunities for BRAF kinase inhibitor drugs manufacturers in the emerging economies. For instance, in September 2016, Novartis International AG secured an Indian patent for its skin cancer (melanoma) drug Tafinlar, which is used for the treatment of metastatic melanoma, the most serious and life-threatening type of skin cancer that is associated with low survival rates.

However, one of the challenges in BRAF kinase inhibitors market is patient adherence. Due to the high cost of BRAF kinase inhibitor drugs, patients are shifting from the actual treatment regime to alternatives of cancer treatments. Alternative methods available for cancer treatments is expected to hinder growth of the BRAF kinase inhibitors market in the near future. For instance, metastatic cancer requires systemic therapy or medications given through mouth or injected into the bloodstream to reach cancer cells throughout the body such as chemotherapy or hormone therapy. Other treatments may include immunotherapy, radiation therapy, surgery or a combination of these.

Key features of the study:

This report provides in-depth analysis of the global BRAF kinase inhibitors market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year

It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players

It profiles key players in the global BRAF kinase inhibitors market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies

Key players covered as a part of this study include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.

Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics

The global BRAF kinase inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for BRAF kinase inhibitors market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

Global BRAF Kinase Inhibitors Market, By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
Global BRAF Kinase Inhibitors Market, By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
Global BRAF Kinase Inhibitors Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global BRAF Kinase Inhibitors Market, By Region:
- North America
  - By Country:
- U.S.
- Canada
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Europe
  - By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Asia Pacific
  - By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America
  - By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Middle East
  - By Country:
- GCC
- Israel
- Rest of Middle East
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Africa
  - By Country/Region:
- South Africa
- Central Africa
  - By Drug:
- Vemurafenib
- Dabrafenib
- Lifirafenib
- Encorafenib
  - By Indication:
- Metastatic Melanoma
- Metastatic Lung Cancer
- Others
  - By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles
- F. Hoffmann-La Roche AG*
  - Company Overview
  - Product Portfolio
  - Financial Performance
  - Recent Highlights
  - Strategies
- Novartis International AG
- Pfizer, Inc.

"" marked represents similar segmentation in other categories in the respective section.*

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Overview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Market Opportunities
Impact Analysis
Product Launches
Key Developments
Regulatory Scenario
PEST Analysis
Treatment Evolution
Pipeline Analysis
Reimbursement Scenario

4. Impact of COVID-19 on BRAF Kinase Inhibitors Market

Supply Side And Demand Side Analysis
Overall Impact
Impact on Research and Development

5. Global BRAF Kinase Inhibitors Market, By Drug, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Vemurafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Dabrafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Lifirafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Encorafenib
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global BRAF Kinase Inhibitors Market, By Indication, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Metastatic Melanoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Metastatic Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global BRAF Kinase Inhibitors Market, By Distribution Channel, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, 2017 - 2028
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

8. Global BRAF Kinase Inhibitors Market, By Region, 2017 - 2028, (US$ Million)

Introduction
- Market Share Analysis, By Region, 2022 and 2028 (%)
- Y-o-Y Growth Analysis, By Region, 2017 - 2028
- Regional Trends
North America
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.S.
- Canada
Europe
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- U.K.
- Germany
- Italy
- France
- Spain
- Russia
- Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- China
- Japan
- India
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
Latin America
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
Middle East
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
- GCC Countries
- Israel
- Rest of Middle East
Africa
- Market Size and Forecast, By Drug, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Indication, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Million)
- Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
- North Africa
- Central Africa
- South Africa

9. Competitive Landscape

Company Profiles
- F. Hoffmann-La Roche AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Novartis International AG
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies
- Pfizer, Inc.
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Highlights
- Strategies

10. Section

References
Research Methodology
About us and Sales Contact

BRAFキナーゼ阻害剤の世界市場：薬剤別、適応症別、流通チャネル別、地域別-規模、シェア、展望、機会分析-2022～2028年

BRAF Kinase Inhibitors Market, by Drug, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章調査目的・前提条件

第2章市場概要

第3章市場力学、規制、および動向分析

第4章 BRAFキナーゼ阻害剤市場に対するCOVID-19の影響

第5章世界のBRAFキナーゼ阻害剤市場：薬剤別（2017～2028年（100万米ドル））

第6章世界のBRAFキナーゼ阻害剤市場：適応症別（2017～2028年（100万米ドル））

第7章世界のBRAFキナーゼ阻害剤市場：流通チャネル別（2017～2028年（100万米ドル））

第8章世界のBRAFキナーゼ阻害剤市場：地域別（2017～2028年（100万米ドル））

第9章競合情勢

第10章セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

"" marked represents similar segmentation in other categories in the respective section.*

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Impact of COVID-19 on BRAF Kinase Inhibitors Market

5. Global BRAF Kinase Inhibitors Market, By Drug, 2017 - 2028, (US$ Million)

6. Global BRAF Kinase Inhibitors Market, By Indication, 2017 - 2028, (US$ Million)

7. Global BRAF Kinase Inhibitors Market, By Distribution Channel, 2017 - 2028, (US$ Million)

8. Global BRAF Kinase Inhibitors Market, By Region, 2017 - 2028, (US$ Million)

9. Competitive Landscape

10. Section

BRAFキナーゼ阻害剤の世界市場：薬剤別、適応症別、流通チャネル別、地域別-規模、シェア、展望、機会分析-2022～2028年

BRAF Kinase Inhibitors Market, by Drug, by Indication, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

目次

第1章 調査目的・前提条件

第2章 市場概要

第3章 市場力学、規制、および動向分析

第4章 BRAFキナーゼ阻害剤市場に対するCOVID-19の影響

第5章 世界のBRAFキナーゼ阻害剤市場：薬剤別（2017～2028年（100万米ドル））

第6章 世界のBRAFキナーゼ阻害剤市場：適応症別（2017～2028年（100万米ドル））

第7章 世界のBRAFキナーゼ阻害剤市場：流通チャネル別（2017～2028年（100万米ドル））

第8章 世界のBRAFキナーゼ阻害剤市場：地域別（2017～2028年（100万米ドル））

第9章 競合情勢

第10章 セクション

Market Dynamics

Key features of the study:

Detailed Segmentation:

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

2. Market Overview

3. Market Dynamics, Regulations, and Trends Analysis

4. Impact of COVID-19 on BRAF Kinase Inhibitors Market

5. Global BRAF Kinase Inhibitors Market, By Drug, 2017 - 2028, (US$ Million)

6. Global BRAF Kinase Inhibitors Market, By Indication, 2017 - 2028, (US$ Million)

7. Global BRAF Kinase Inhibitors Market, By Distribution Channel, 2017 - 2028, (US$ Million)

8. Global BRAF Kinase Inhibitors Market, By Region, 2017 - 2028, (US$ Million)

9. Competitive Landscape

10. Section

第1章調査目的・前提条件

第2章市場概要

第3章市場力学、規制、および動向分析

第5章世界のBRAFキナーゼ阻害剤市場：薬剤別（2017～2028年（100万米ドル））

第6章世界のBRAFキナーゼ阻害剤市場：適応症別（2017～2028年（100万米ドル））

第7章世界のBRAFキナーゼ阻害剤市場：流通チャネル別（2017～2028年（100万米ドル））

第8章世界のBRAFキナーゼ阻害剤市場：地域別（2017～2028年（100万米ドル））

第9章競合情勢

第10章セクション

"" marked represents similar segmentation in other categories in the respective section.*